# Food and Drug Administration (FDA) Type: organization Source: GetYourBrief — https://getyourbrief.com/entity/food-and-drug-administration-fda Canonical HTML page: https://getyourbrief.com/entity/food-and-drug-administration-fda ## Timeline - **2026-07**: ALJ Hearing on Marijuana Rescheduling — A seven-day administrative hearing is held in Arlington, Virginia, debating whether marijuana has a 'currently accepted medical use' without MMJ's testimony or evidence. - **2026-06**: DEA Excludes MMJ from Rescheduling Hearing — The DEA denies MMJ International Holdings' request to participate in the upcoming administrative hearing, asserting that its evidence raises only questions of law. - **2026-05-03**: Federal Appeals Court Bans Mailing Mifepristone — A federal appeals court made it illegal to mail mifepristone, a key medication abortion pill, threatening telehealth access. - **2026-05**: Supreme Court Issues Stay on Mifepristone Ban — The Supreme Court stayed the appeals court ruling, allowing mailing to continue while the legal challenge proceeds. - **2026-Q2 (projected)**: Legal Challenges — Expected filing of lawsuits by environmental groups to block the relaxation of standards. - **2026-03-13**: EPA Rollback Proposal — The EPA announces moves to weaken the previously established pollution limits. - **2026-03-08**: Industry Consensus — Scientific American and other major outlets report a definitive decline in global animal experiment volumes. - **2025-Q3**: Industry Petitions — Medical tech groups and the FDA raise alarms about potential device shortages due to facility closures. - **2024-11-10**: Major CRO Pivot — Leading Contract Research Organizations announce multi-million dollar investments in digital twin and OOC labs. - **2024-03**: Strict Standards Finalized — EPA issues a rule requiring a 90% reduction in EtO emissions from sterilization plants. - **2023-06-15**: FDA Guidance on NAMs — The FDA issues initial framework for the submission of data derived from microphysiological systems. - **2022-12-29**: FDA Modernization Act 2.0 — President Biden signs legislation ending the mandate for animal testing for new drug applications. - **2022-06-24**: Supreme Court Overturns Roe v. Wade in Dobbs Decision — The landmark ruling eliminated the constitutional right to abortion, allowing states to enact bans. ## Recent coverage (12 stories, network-wide) ### 5,100 Suspected Cyclospora Cases Drive Demand for Rapid Diagnostics and New Therapies 2026-07-15 22:57:53 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 75 The CDC's health alert on a cyclosporiasis outbreak with 5,100 suspected cases presents urgent needs in the biotech sector for rapid diagnostics, antiparasitic drug development, and food safety technologies. The parasite Cyclospora cayetanensis, with its long incubation period, challenges traditional detection methods, while treatment relies on a decades-old antibiotic. Innovators could capitalize on multiplex PCR panels and next-generation sequencing for outbreak tracking. Full story: https://getbiobrief.com/story/cyclospora-outbreak-diagnostics-therapies-bio ### DEA Excluded MMJ, Only FDA-Pathway Developer with $10M in Research, from Rescheduling Hearing 2026-07-13 06:01:24 · Sector: legal · Sentiment: Neutral · Impact: 6/10 · Sources: 2 MMJ International Holdings alleges the DEA violated administrative law by excluding it from marijuana rescheduling hearings, despite spending $10 million on FDA-pathway development. The exclusion raises due process and APA concerns that could imperil the final rule. Full story: https://getlegalbrief.com/story/dea-excludes-mmj-fda-cannabinoid-rescheduling-hearing ### Abortions Surge 100% Post-Roe: How Telehealth Pills Exploit Legal Gaps 2026-06-28 09:16:18 · Sector: legal · Sentiment: Neutral · Impact: 7/10 · Sources: 23 Despite state bans, U.S. abortions nearly doubled, fueled by telehealth pill delivery across state lines. This exposes legal tensions between state authority, FDA preemption, and 19th-century obscenity statutes. Full story: https://getlegalbrief.com/story/abortions-surge-telehealth-legal ### Abortions Nearly Double to 20% via Telehealth Pills: New Healthcare Era 2026-06-28 09:16:05 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 23 U.S. abortions nearly doubled between 2021 and 2025, with medication abortion now 63% of the total. Telehealth delivery has enabled this surge, though misoprostol-only use raises clinical concerns. Full story: https://gethealthbrief.com/story/abortion-doubling-telehealth-pills ### Peptide Supply Crisis Deepens as Major Industry Provider Ceases Operations 2026-03-20 19:52:00 · Sector: bio · Sentiment: Negative · Impact: 6/10 · Sources: 2 The sudden closure of a primary peptide supplier has sent shockwaves through the biotech research community, significantly reducing the availability of high-purity compounds. Nova Life Peptides warns that this contraction will likely lead to increased costs and delayed timelines for preclinical studies. Full story: https://getbiobrief.com/story/major-peptide-supplier-shutdown-nova-life-peptides ### EPA Signals Regulatory Pivot by Weakening Medical Sterilization Emission Limits 2026-03-13 21:21:24 · Sector: legal · Sentiment: Negative · Impact: 7/10 · Sources: 3 The Environmental Protection Agency has proposed a relaxation of pollution standards for chemicals used in medical equipment sterilization, specifically targeting Ethylene Oxide (EtO). This move attempts to balance carcinogenic health risks against the critical need to maintain the national medical device supply chain. Full story: https://getlegalbrief.com/story/epa-weakens-medical-sterilization-pollution-limits ### Wellness Supplement Recalled After Undeclared Viagra Ingredient Discovery 2026-03-13 17:38:37 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 46 A nationwide recall has been issued for a wellness supplement following the discovery of sildenafil, the active ingredient in the prescription drug Viagra. The presence of this undeclared pharmaceutical poses severe health risks, particularly through potentially fatal interactions with common heart medications. Full story: https://gethealthbrief.com/story/wellness-supplement-recall-viagra-ingredient ### The DTC Debate: Assessing the Future of Pharma Advertising in the U.S. 2026-03-09 11:46:34 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3 The pharmaceutical industry faces renewed scrutiny over direct-to-consumer (DTC) advertising, a practice unique to the U.S. and New Zealand. As healthcare costs rise, regulators are weighing the educational benefits of these ads against their role in driving up prescription volumes and drug prices. Full story: https://getbiobrief.com/story/pharma-dtc-advertising-regulation-analysis ### The Battle Over the Airwaves: Reevaluating Direct-to-Consumer Drug Advertising 2026-03-09 11:46:01 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 3 A renewed public debate over Direct-to-Consumer Advertising (DTCA) is challenging the pharmaceutical industry's marketing status quo in the United States. As healthcare costs escalate, regulators and lawmakers are weighing the educational benefits of patient outreach against the risks of over-prescription and inflated drug prices. Full story: https://gethealthbrief.com/story/direct-to-consumer-drug-advertising-regulation-debate ### The Twilight of Animal Testing: Pharma’s Shift to Human-Centric Models 2026-03-08 18:30:48 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2 The pharmaceutical industry is undergoing a paradigm shift as regulatory changes and technological breakthroughs reduce reliance on animal models. With the FDA Modernization Act 2.0 paving the way, human-on-a-chip and AI-driven simulations are emerging as more predictive alternatives for drug safety and efficacy. Full story: https://getbiobrief.com/story/animal-testing-waning-biotech-innovation ### The Post-Animal Era: Regulatory Shifts and Tech Innovation Disrupt Drug R&D 2026-03-08 18:25:48 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2 The long-standing paradigm of animal experimentation is facing an unprecedented decline as regulatory frameworks and advanced biotechnologies converge. Following the landmark FDA Modernization Act 2.0, the industry is pivoting toward 'New Approach Methodologies' that promise higher human predictive value and lower development costs. Full story: https://gethealthbrief.com/story/animal-testing-decline-healthcare-regulation ### FDA to Incentivize Faster Drug Approvals via New Staff Bonus Program 2026-02-26 23:36:59 · Sector: legal · Sentiment: Positive · Impact: 7/10 · Sources: 5 The U.S. Food and Drug Administration is implementing a performance-based bonus structure to reward staffers who complete drug reviews ahead of schedule. This initiative aims to accelerate the therapeutic pipeline but has sparked immediate debate over the potential impact on safety standards and regulatory rigor. Full story: https://getlegalbrief.com/story/fda-bonus-payments-speedy-drug-reviews --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.